Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about microtubule_stabilization: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| axonal_transport | enables | process | 0.80 |
| Source | Relation | Type | Str |
|---|---|---|---|
| MAP6 | regulates | gene | 0.80 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Tau-Independent Microtubule Stabilization via MAP6 Enhanceme | 0.567 | neurodegeneration | Selective vulnerability of entorhinal co |
| MAP6-mediated microtubule stabilization as therapeutic targe | 0.500 | neurodegeneration | View |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.696
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| MAP6 depletion effects on neuronal development in primary cultures | exploratory | 0.900 | 0.00 | primary rodent neuronal cultur | proposed | N/A | |
| MAP6 depletion effects on neuronal development in primary cultures | exploratory | 0.900 | 0.00 | primary rodent neuronal cultur | proposed | N/A | |
| In vivo neuronal migration assay with MAP6 depletion | validation | 0.850 | 0.00 | rodent in vivo model | proposed | N/A | |
| 4R-Tau Targeting Therapies for PSP and CBS | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Anti-Tau Immunotherapy Dosing Optimization | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy in 4R-Tau | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $170,000 |
| Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Trials Have N | clinical | ALS | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Axonal Transport Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Blood Biomarker vs Tau PET for Treatment Monitoring | clinical | ALS | 0.400 | 0.50 | human | proposed | $5,460,000 |
| CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omics Study | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $160,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Tau and MAP6 establish labile and stable domains on microtubules. [PMID:40040809] | Kirimtay K, Huang W, Sun X, Qiang L, Wan | iScience | 2025 | 1 |
| Antagonistic roles of tau and MAP6 in regulating neuronal development. [PMID:39257379] | Sun X, Yu W, Baas PW, Toyooka K, Qiang L | J Cell Sci | 2024 | 1 |
| Beyond Neuronal Microtubule Stabilization: MAP6 and CRMPS, Two Converging Storie [PMID:34025352] | Cuveillier C, Boulan B, Ravanello C, Den | Front Mol Neurosci | 2021 | 1 |
| Tau: It's Not What You Think. [PMID:30929793] | Baas PW, Qiang L | Trends Cell Biol | 2019 | 1 |
| Stability properties of neuronal microtubules. [PMID:26887570] | Baas PW, Rao AN, Matamoros AJ, Leo L | Cytoskeleton (Hoboken) | 2016 | 1 |
| Targeting CXCL16-expressing macrophages with a biomimetic nanocarrier system att [PMID:41707770] | Yang Q, Xu Y, Zhan Y, Li J, Peng R, Yu B | Journal of controlled release | 2026 | 0 |
| The MAP6-NTS axis in hippocampal CA1 regulates synaptic plasticity and memory. [PMID:41825505] | Jia Y, Lei J, Jiang Y, Xue L, Chen T, Wa | Neuropharmacology | 2026 | 0 |
| BioID2-Based Tau Interactome Reveals Novel and Known Protein Interactions Associ [PMID:40910579] | Atwa A, Alhadidy MM, Lamp J, Combs B, Ka | Journal of proteome research | 2025 | 0 |
| Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acid [PMID:40533746] | ["Sanadgol N", "Abedi M", "Hashemzaei M" | Journal of nanobiotechnology | 2025 | 0 |
| ReMAPping the microtubule landscape: How phosphorylation dictates the activities [PMID:28980356] | Ramkumar A, Jong BY, Ori-McKenney KM | Developmental dynamics : an of | 2018 | 0 |
| Inferring patterns of folktale diffusion using genomic data. [PMID:28784786] | ["Bortolini E", "Pagani L", "Crema E", " | Proceedings of the National Ac | 2017 | 0 |
| Purification and Characterization of Progenitor and Mature Human Astrocytes Reve [PMID:26687838] | ["Zhang Y", "Sloan S", "Clarke L", "Cane | Neuron | 2016 | 0 |
| Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severin [PMID:24065130] | ["Zempel H", "Luedtke J", "Kumar Y", "Bi | The EMBO journal | 2013 | 0 |
| Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). [PMID:21902667] | Gozes I | Current pharmaceutical design | 2011 | 0 |
| Decreased neuroautonomic complexity in men during an acute major depressive epis [PMID:22832529] | ["Leistedt S", "Linkowski P", "Lanquart | Translational psychiatry | 2011 | 0 |
| Bidirectional activity-dependent plasticity at corticostriatal synapses. [PMID:16339023] | ["Fino E", "Glowinski J", "Venance L"] | The Journal of neuroscience : | 2005 | 0 |
| STOP proteins. [PMID:14567673] | Bosc C, Andrieux A, Job D | Biochemistry | 2003 | 0 |
| Ebselen: a substrate for human thioredoxin reductase strongly stimulating its hy [PMID:12070343] | ["Zhao R", "Masayasu H", "Holmgren A"] | Proceedings of the National Ac | 2002 | 0 |
| STOP proteins. [PMID:15218867] | Bosc C, Oenarier E, Andrieux A, Job D | Cell structure and function | 1999 | 0 |
Multi-agent debates referencing this entity
Hypotheses and analyses mentioning microtubule_stabilization in their description or question text
No additional research found